

TEMPLE UNIVERSITY  
INSTITUTIONAL BIOSAFETY COMMITTEE  
IBC Meeting Minutes- Online Meeting  
March 17, 2026 12:00 pm

**Members**

|   |                                                          |
|---|----------------------------------------------------------|
| X | Black, Dr. Mark- Community Member                        |
| X | Bradley, Carlos- Community Member                        |
| X | Culmer-Butler, Dr. Dorian- Animal Containment Expert     |
| X | Escalante, Dr. Ananias- Scientist                        |
| X | Forste, Dr. Dawn- Animal Containment Expert              |
| X | Gallo, Dr. Gianluca- Scientist                           |
| X | Lupinski, Gregory- EHRS Executive Director               |
|   | Mobo, Dr. Ben Hur Jr.- Occupational Health Administrator |
| X | Moore, Claudia- IACUC Asst. Director                     |
| X | Murray, Krista- IBC Assistant Director                   |
| X | Pultro, Mary- IBC Sr. Coordinator                        |
| X | Sariyer, Dr. Ilker- IBC Vice-Chair, Scientist            |
| X | Sawaya, Dr. Bassel- Scientist                            |
| X | Sulistijo, Dr. Endah- University Biosafety Officer       |
| X | Tsygankov, Dr. Alexander- IBC Chair, Scientist           |
| X | Whelan, Dr. Kelly- Scientist                             |
| X | Wimmer, Dr. Mathieu- Scientist                           |

X= Present

Quorum was met for this meeting.  
All decisions were unanimous.

**Guests**

Baglia, Frank- Senior Health & Safety Specialist  
Collyer, Eileen- Associate Health & Safety Specialist  
Hao, Lanping- Associate Health & Safety Specialist  
Kidder, Abigail- IACUC Analyst  
Slupianek, Dr. Artur- Senior Director of Research Regulatory Affairs  
Wright, Simone- IBC Analyst

I. Announcements  
None

II. Other Business  
None

III. Minutes Reviewed  
Minutes from the February 17, 2026 meeting were reviewed. The motion to approve the minutes was made and approved unanimously.

#### IV. Protocols Reviewed

|                                                                                                                                                                                                                                           |                   |                          |                     |               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------|---------------------|---------------|
| <b>PI:</b> Ilies, Marc                                                                                                                                                                                                                    | <b>Reg:</b> 11345 | <b>Activity:</b> New BRF | <b>NIH:</b> III-E-1 | <b>BSL:</b> 1 |
| <b>Title:</b> Carbonic Anhydrase Isozyme Expression, Purification, and Testing                                                                                                                                                            |                   |                          |                     |               |
| <b>Overview:</b> Establish a platform for the recombinant expression, purification, and functional validation of multiple human carbonic anhydrase isoforms.                                                                              |                   |                          |                     |               |
| <b>Discussion:</b> The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need administrative modifications including storage and research locations. |                   |                          |                     |               |
| <b>Final Action:</b> modifications required                                                                                                                                                                                               |                   |                          |                     |               |

|                                                                                                                                                                                                                                                                                  |                    |                            |                              |               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------|------------------------------|---------------|
| <b>PI:</b> Wei, Juncheng                                                                                                                                                                                                                                                         | <b>Reg.:</b> 11136 | <b>Activity:</b> Amendment | <b>NIH:</b> III-D-4; III-E-1 | <b>BSL:</b> 2 |
| <b>Title:</b> The Role of E3 and DUB in Metabolism and Autoimmunity                                                                                                                                                                                                              |                    |                            |                              |               |
| <b>Overview:</b> Addition of AAVs for in vitro work.                                                                                                                                                                                                                             |                    |                            |                              |               |
| <b>Discussion:</b> The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need additional description of how the AAVs will be used, and whether they will be produced in-house or purchased. |                    |                            |                              |               |
| <b>Final Action:</b> modifications required                                                                                                                                                                                                                                      |                    |                            |                              |               |

|                                                                                                                                                                                                                        |                    |                            |                     |               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------|---------------------|---------------|
| <b>PI:</b> Yang, Weidong                                                                                                                                                                                               | <b>Reg.:</b> 11096 | <b>Activity:</b> Amendment | <b>NIH:</b> III-E-1 | <b>BSL:</b> 2 |
| <b>Title:</b> Super-Resolution Microscopy Study of Molecular Transport Mechanism                                                                                                                                       |                    |                            |                     |               |
| <b>Overview:</b> Addition of AAVs for in vitro research.                                                                                                                                                               |                    |                            |                     |               |
| <b>Discussion:</b> The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need additional description of how the AAV will be used. |                    |                            |                     |               |
| <b>Final Action:</b> modifications required                                                                                                                                                                            |                    |                            |                     |               |

|                                                                                                                                                               |                    |                            |                                 |               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------|---------------------------------|---------------|
| <b>PI:</b> Liu-Chen, Lee-Yuan                                                                                                                                 | <b>Reg.:</b> 11289 | <b>Activity:</b> Amendment | <b>NIH:</b> III-D-1, 4; III-E-1 | <b>BSL:</b> 2 |
| <b>Title:</b> In vitro and In vivo Characterization of Kappa Opioid Receptor                                                                                  |                    |                            |                                 |               |
| <b>Overview:</b> Addition of an AAV for intracranial microinfusion.                                                                                           |                    |                            |                                 |               |
| <b>Discussion:</b> The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. |                    |                            |                                 |               |
| <b>Final Action:</b> approved                                                                                                                                 |                    |                            |                                 |               |

|                                                                                                                                                                                                                                                            |                    |                            |                                          |               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------|------------------------------------------|---------------|
| <b>PI:</b> Elrod, John                                                                                                                                                                                                                                     | <b>Reg.:</b> 11101 | <b>Activity:</b> Amendment | <b>NIH:</b> III-D-1, 2, 3, 4; III-E-1, 3 | <b>BSL:</b> 2 |
| <b>Title:</b> Mitochondrial Calcium Exchange in Heart Disease                                                                                                                                                                                              |                    |                            |                                          |               |
| <b>Overview:</b> Addition of AAV and bleomycin for in vivo procedures.                                                                                                                                                                                     |                    |                            |                                          |               |
| <b>Discussion:</b> The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need a description of how this fits into the current protocol and some administrative edits. |                    |                            |                                          |               |
| <b>Final Action:</b> modifications required                                                                                                                                                                                                                |                    |                            |                                          |               |

|                                                                                                                                                               |                    |                            |                     |               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------|---------------------|---------------|
| <b>PI:</b> Zhou, Zhengjie                                                                                                                                     | <b>Reg.:</b> 11294 | <b>Activity:</b> Amendment | <b>NIH:</b> III-D-4 | <b>BSL:</b> 2 |
| <b>Title:</b> Precision Nanomedicine Targeting Pulmonary Inflammatory Mechanisms                                                                              |                    |                            |                     |               |
| <b>Overview:</b> Evaluate the effect of siRNA-loaded nanoparticles and treatment of cell cultures with small molecules.                                       |                    |                            |                     |               |
| <b>Discussion:</b> The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. |                    |                            |                     |               |
| <b>Final Action:</b> approved                                                                                                                                 |                    |                            |                     |               |

V. Adjournment

The motion to adjourn the meeting was approved unanimously; the meeting adjourned at 12:33 pm.

Respectfully submitted,

*Krista Murray*

Krista Murray  
Institutional Biosafety Committee Assistant Director